Division of Molecular Medicine, Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Nat Struct Mol Biol. 2010 Dec;17(12):1486-91. doi: 10.1038/nsmb.1950. Epub 2010 Nov 14.
HIV-1 envelope glycoprotein gp41 undergoes large conformational changes to drive fusion of viral and target cell membranes, adopting at least three distinct conformations during the viral entry process. Neutralizing antibodies against gp41 block HIV-1 infection by targeting gp41's membrane-proximal external region in a fusion-intermediate state. Here we report biochemical and structural evidence that non-neutralizing antibodies, capable of binding with high affinity to an immunodominant segment adjacent to the neutralizing epitopes in the membrane-proximal region, recognize a gp41 conformation that exists only when membrane fusion is complete. We propose that these non-neutralizing antibodies are induced in HIV-1-infected individuals by gp41 in a triggered, postfusion form and contribute to production of ineffective humoral responses. These results have important implications for gp41-based vaccine design.
HIV-1 包膜糖蛋白 gp41 发生大的构象变化以驱动病毒和靶细胞膜融合,在病毒进入过程中至少采用三种不同构象。针对 gp41 的膜近端外部区域的融合中间状态的中和抗体通过靶向 gp41 来阻断 HIV-1 感染。在此,我们报告生化和结构证据表明,能够以高亲和力结合到中和表位附近的免疫显性片段的非中和抗体识别仅在膜融合完全时存在的 gp41 构象。我们提出,这些非中和抗体是由 HIV-1 感染个体中的 gp41 以触发的、融合后的形式诱导产生的,并有助于产生无效的体液免疫反应。这些结果对基于 gp41 的疫苗设计具有重要意义。